Bowei New Materials: A Value-Investing Deep Dive

[Biggest uncertainties] First, whether photovoltaic "silver reduction/silver substitution," copper-based materials, and other new applications can actually convert into high-quality cash flow over the next two to three years, rather than only into stories and order expectations. Second, whether returns on expanded capacity will be high enough. Capex rose markedly in 2025, and in 2026 the company announced a new 640-tonne ultrafine metal powder materials project. Third, whether governance and capital-allocation quality can improve. Over the past three years the company has received regulatory cautions from the Shanghai Stock Exchange and a warning letter from the Jiangsu securities regulator, and in 2025 it made a related-party investment with limited relevance to its core business.

The Business and the Industry

[Fact] At its core, the company sells "high-end metal powder materials," not end-market brands. Its revenue comes from selling nickel-based, copper-based, silver, and alloy powders to downstream electronic-component or paste customers; within 2025 core-business revenue, nickel-based products were 862 million yuan, copper-based products 121 million yuan, silver powder 53 million yuan, and alloys 27 million yuan. Sales are led by direct sales, with 2025 direct-sales revenue of 997 million yuan and distribution revenue of 65 million yuan.

On the question of "can it be understood," it can be, but it is not extremely simple. It does not earn money through traffic, brand, or store expansion, but through powder-making process, particle-size control, quality consistency, customer qualification, and scaled manufacturing. The company's website and public materials repeatedly stress that it prepares ultrafine metal powders via physical vapor condensation under atmospheric pressure, and that it is the sole drafter and author of the "Capacitor Electrode Nickel Powder" industry standard.

One important feature of this business: the products are consumables, yet demand is unstable. On one hand, downstream markets like MLCCs, photovoltaic conductive materials, and inductor materials carry long-term demand; on the other, the company explicitly states in its annual report that its business cycle is highly correlated with the macro economy and the electronics industry cycle, and that downstream MLCC market demand fell in 2022 and 2023 amid weaker end-market consumer electronics demand. In other words, this is not "subscription revenue" but classic order-driven industrial-materials revenue.

[Fact] It carries some reliance on a small number of customers and suppliers. The company disclosed that in 2025 its top five customers accounted for 78.32% of sales and its top five suppliers for 74.61% of purchases; while no single customer or single supplier exceeded 50%, concentration is already not low. The company also disclosed a strategic nickel-powder cooperation agreement with "Company X," with a performed amount of 233 million yuan from August to December 2025.

[Inference] This means Bowei looks more like a high-barrier but not highly diversified B2B materials supplier. Once customers qualify it, repeat orders can be solid; but if a major customer adjusts its cadence, changes its product roadmap, or shifts its inventory cycle, the company's revenue and profit will swing significantly.

[Fact] Within its cost structure, raw materials remain critical. In its risk disclosures the company states plainly that when raw-material prices rise, failure to pass through costs in time, or a lag in price transmission, can hurt operating results. The 2025 swing in financial expenses was also tied to lower exchange gains, and the company had a sizable USD-denominated foreign-currency receivable balance at year-end.

[Inference] This shows it has some product strength but limited pricing power. In the face of upstream metal-price swings and exchange-rate moves, it is not the kind of consumer-brand company that "raises prices whenever it wants." Its 2025 export gross margin of 49.23% was well above the 13.11% domestic margin, which reflects customer, regional, and product mix more than any broad, durable, unconditional pricing power.

[Industry view] On the demand side, MLCC higher-capacitance, miniaturization, and automotive adoption, along with AI servers, automotive electronics, and photovoltaic silver reduction, give high-end metal powders a medium-to-long-term opportunity; on the supply side, this is a niche that requires process know-how, qualification cycles, and consistency capability. It is not a bad industry, but it is by no means an "easy-money" one. More precisely, it is a midstream materials company within a decent niche, not "a great business model in a great industry."

[Understandability score] 4/5. [Industry attractiveness score] 3/5. If the stock market closed for 5 years, I would be willing to hold a process-driven materials company like this at a reasonable price; but at 165.8 yuan, I would not be willing to take it on as a "whole-business acquisition target."

Moat and Management

[Fact] Bowei's moat is mainly not brand but process, standards, qualification, and quality systems. As of year-end 2025 the company held 181 currently valid granted patents, of which 144 were domestic patents, 64 invention patents, and 37 overseas patents; it is also the sole drafter and author of the "Capacitor Electrode Nickel Powder" industry standard, and a wholly owned subsidiary participated in drafting related group standards. The company holds ISO9001 and IATF-16949 quality-management certifications and disclosed long-standing cooperation with leading domestic and international electronic-component firms in Korea, Taiwan, and elsewhere.

[Inference] So its moat looks more like a manufacturing moat: not network effects, not data advantage, not a consumer-brand monopoly; but customer qualification, product consistency, accumulated process expertise, material formulation, and batch-to-batch stability. This kind of moat is real, but it is usually less stable than a consumer-brand moat, because it still bears the pressure of cycles, customer bargaining, and technology-path substitution.

[Fact] On "can it raise prices in an inflationary environment," the company's own answer leans cautious. Its annual-report risk disclosure clearly states that when raw-material prices rise, failure to pass through costs in time or a lag in price transmission will hurt profitability. At the same time, the company posted a loss in 2023, showing it cannot reliably sustain high profitability during downturns.

[Opinion] So my assessment of its moat is: it exists, but it is not strong enough to ignore the cycle; it is stable, but not strong enough to support a PB above 20x. It looks closer to "the embryo of a technical small-oligopoly" than "a Coca-Cola-style moat."

On management, start with the positives. [Fact] The actual controller is Wang Liping, the current chairman; controlling shareholder Guang Hongyuan holds 19.71%, and concert party Shenyang Investment holds 6.88%, together controlling about 26.59% of the shares. The company also disclosed that Chairman Wang Liping has more than 20 years of operating and management experience in metal powder materials, and its technical adviser has more than 30 years of metal-powder R&D experience.

This means there is interest alignment, the founder remains deeply involved in operations, and the technical and market paths have continuity. In 2025 R&D expense was 47.994 million yuan, R&D intensity was 4.17% of revenue, and there were 119 R&D staff, 10.85% of the total workforce, showing the company has not stopped investing as a "technology-driven enterprise."

But I cannot give management a high mark, because the negative evidence is just as clear. [Fact] In September 2023 the company received a regulatory caution from the Shanghai Stock Exchange for failing to follow board-review procedures and disclosure obligations on a delayed fundraising-project; in January 2025 it received a warning letter from the Jiangsu securities regulator, which cited disclosure errors on the construction progress of a fundraising project in H1 2021, a failure to disclose a project delay in time in H1 2022, a misstatement of non-recurring items in the 2023 annual report that overstated deducted net profit by 1.1681 million yuan, and inaccurate disclosure of changes among the top five suppliers.

[Fact] In 2025 the company did not conduct any share buybacks, and its annual report clearly disclosed that total shares were unchanged during the period; but in April 2026 the company launched preliminary preparations to issue H shares overseas and list in Hong Kong.

[Fact] On capital allocation, the 2025 dividend proposal was 1.0 yuan per 10 shares, totaling 26.16 million yuan, about 11.9% of 2025 net profit attributable to shareholders; the 2024 dividend proposal was 1.5 yuan per 10 shares, totaling 39.24 million yuan, about 44.9% of 2024 net profit attributable to shareholders. In other words, even with profit sharply recovering in 2025, the company markedly cut its payout ratio and retained more cash internally.

This in itself is not necessarily bad, since both capacity expansion and R&D need money; what truly puts me on guard is whether the cash always stays focused on the core business. [Fact] In 2025 the company used a combined 75 million yuan of own or self-raised funds to acquire a 9.1463% stake in Huchuang Medical, a transaction that constituted a related-party co-investment; in addition, a subsidiary had earlier bought 20 residential units for housing technical R&D staff and mid-to-senior managers, at a price of 30.3488 million yuan.

[Inference] For a materials company with a very high market cap but unstable free cash flow, this mix of "core-business expansion + related-party investment + employee-housing arrangements + H-share preparation" does not leave me especially comfortable. It is not obviously poor governance, but neither is it the kind of "extremely disciplined capital allocation focused solely on growing intrinsic value per share."

[Moat-strength score] 3/5. [Management and capital-allocation score] 2.5/5.

Financial Quality and Owner Earnings

First, a compressed historical table. All figures are in hundred millions of yuan, and ROE is the weighted average return on equity the company disclosed.

Note: 2019-2021 figures are from the 2021 annual-report summary; 2022-2024 from the 2024 annual report; 2025 from the 2025 annual-report correction announcement and the annual-report text.

[Fact] Connecting 2019 to 2025, revenue compounded at about 15.7%, but net profit attributable to shareholders compounded at only about 8.5%. The real issue is not "whether there is growth," but that the quality of that growth is very uneven: strong in 2021, falling back in 2022, a loss in 2023, a recovery in 2024, and another sharp rebound in 2025.

On margins, the 2023-2025 recovery is very clear. Estimated from revenue and operating cost, the company's blended gross margin moved from roughly 15.0% in 2023 to about 20.9% in 2024 and then to about 32.6% in 2025. By product in 2025, gross margin was 37.54% for nickel-based products, 26.87% for copper-based products, 6.81% for silver powder, and 62.13% for alloys; by region, domestic-sales gross margin was 13.11% and export gross margin 49.23%.

[Inference] This set of figures matters, because it shows the high 2025 margins came at least partly from improved product and regional mix, and should not simply be read as "the company has entered a permanently high-profit state." That export margin far exceeds the domestic margin looks more like mix improvement than broad, across-the-board pricing power. Put differently, 2025 profit quality is better than 2023 or 2024, but does not necessarily represent a steady state that can be extrapolated linearly.

Cash flow is the single most important link in judging this company. [Fact] Net operating cash flow was 295 million yuan in 2024 and fell to 135 million yuan in 2025, which the company attributes mainly to higher raw-material purchases in the period. In Q1 2026, revenue rose to 410 million yuan and net profit attributable to shareholders to 71.63 million yuan, but net operating cash flow was -149 million yuan.

[Inference] This means the relationship between accounting profit and cash profit is not stable. Against 2025 net profit of 219 million yuan, operating cash flow was only 135 million yuan, a profit-to-cash conversion rate of about 61%; across 2021-2025 the cash-flow record swings even more, showing the company is still a clear distance from a mature, "steady cash-spewing" cash cow. As a value investor, what you are really paying for is future free cash flow, not the profit peak of a single year.

Free cash flow is even more telling. [Fact] In 2025 the company spent 251 million yuan of cash on purchasing and building fixed assets, intangible assets, and other long-term assets, against net operating cash flow of 135 million yuan, for free cash flow of about -117 million yuan; on the same basis in 2024, free cash flow was about +195 million yuan. At the same time, construction in progress rose from 40.41 million yuan to 136 million yuan in 2025, and net cash outflow from investing widened to 321 million yuan, mainly from higher spending on civil works and production-equipment construction.

[Inference] This shows the company has reinvestment opportunities, but it also shows its growth is not "light." Today's Bowei is not "easier the more it grows," but a company where growth often comes with capex and working-capital absorption. If the returns on new capacity are very high in the future, this is fine; but if returns are mediocre, then whoever buys at today's high valuation will pay the price of years of less-than-ideal cash returns.

On the balance sheet, things are not so dire. [Fact] On the restated basis, year-end 2025 total assets were 2.265 billion yuan and net assets attributable to shareholders 1.715 billion yuan, implying a debt-to-asset ratio of about 24.3%. Short-term borrowings were 260 million yuan, non-current liabilities due within one year 2.7869 million yuan, and lease liabilities 8.7827 million yuan; cash and bank balances were 43.2482 million yuan, and the cash-and-cash-equivalents balance was 37.22 million yuan. On a rough 2025 EBITDA basis, net debt/EBITDA is about 0.6x, and an interest-coverage estimate using EBIT/financial expenses is above 40x.

[Opinion] So it is not a company facing immediate financial distress, and its survivability is acceptable; but it is also by no means an enterprise "sitting on large net cash with a very loose funding chain." What you are buying is not a balance-sheet cushion, but growth expectations.

Now working capital. [Fact] At year-end 2025, accounts receivable were 307 million yuan, up 66.78% year-on-year; prepayments 42.11 million yuan, up 231.52%; inventory 306 million yuan, up 6.02%; while cash resources fell clearly. The supplementary cash-flow schedule shows that in 2025 "decrease (increase) in operating receivables" was -236 million yuan, "decrease (increase) in inventory" was -34.64 million yuan, and "increase (decrease) in operating payables" was +74.85 million yuan.

[Inference] This set of data makes it hard for me to lightly conclude "high-quality growth." It looks more like: orders and expansion drove a profit rebound, but also locked cash into receivables and working capital. For short-term holders this is especially dangerous, because the stock often rises before profit is recognized; once cash conversion fails to keep up, the valuation gets re-rated fast.

On "is there financial fraud or aggressive accounting," my judgment is: [Fact] The company's 2025 annual report received a standard unqualified audit opinion from Zhonghui CPAs; on April 20, 2026 the company corrected its 2025 annual report and audit report, but stated clearly that this correction did not affect the income statement, revenue, net profit attributable to shareholders, or deducted net profit. At the same time, the company has indeed had disclosure and non-recurring-item misstatement problems over the past three years, and regulators have issued cautions.

[Opinion] I have not seen evidence pointing directly to financial fraud; but neither would I rate its disclosure quality as excellent. More precisely: the audit conclusion is normal, the governance details are not pretty, and this calls for ongoing caution rather than an outright conviction.

Next, an Owner Earnings estimate. On a Buffett-style basis, I care more about "after adding back genuine non-cash charges and deducting the capex needed to maintain operations plus incremental working-capital needs, how much distributable cash is left."

Note: depreciation and amortization is the sum of fixed-asset depreciation, right-of-use-asset amortization, intangible-asset amortization, and long-term deferred-expense amortization; maintenance capex is estimated on a conservative basis close to depreciation and amortization; incremental working-capital absorption is estimated mainly from changes in inventory, operating receivables, and operating payables.

[Inference] This conservative Owner Earnings of around 41 million yuan is harsh, but it reflects the real cash absorption that occurred in 2025. If you believe the 2025 rise in receivables and prepayments is partly transitory, then a neutral-basis Owner Earnings could be relaxed to 100-150 million yuan; but on either basis, against a market cap of about 43.37 billion yuan, the current price implies a still-extreme P/OE: about 700-1,000x on the conservative basis, and still 290-430x on the neutral basis.

Valuation and Margin of Safety

The conclusion up front: at the current price, there is almost no visible margin of safety.

I value it three ways.

Method 1: Owner Earnings discount model

I give three scenarios, where the point is not "guessing the stock price" but asking: how much real cash flow must this company create for today's 165.8 yuan purchase price to be reasonable.

Note: the above are my estimates based on the company's 2025 owner earnings, debt and cash position, and future growth assumptions, where the optimistic scenario already embeds new-business delivery, successful expansion, and fairly strong cash conversion.

[Opinion] Even after granting a very generous optimistic scenario, the resulting value is still far below 165.8 yuan. In other words, buying today means paying the full, or even an excess, price upfront for a very-long-dated new story that must deliver in full.

Based on this method, I set out the following value ranges: Conservative intrinsic-value range: 4-7 yuan/share; Reasonable intrinsic-value range: 10-18 yuan/share; Optimistic intrinsic-value range: 30-50 yuan/share.

Relative to 165.8 yuan, the current price implies a huge premium to each of these ranges. Even against the 50 yuan top of the optimistic range, the current price is still about 232% higher; against the 14 yuan midpoint of the reasonable range, the premium exceeds 1,000%. These ratios are derived directly from the valuation results above.

Method 2: Relative valuation

[Fact] The public market-data page shows Bowei's current trailing PE at about 171.7x and PB at about 23.7x; Yuean New Materials, comparable within the micro-nano metal powder / metal new-materials space, shows on its market-data page a PE of about 61.3x and PB of about 6.6x; Grirem Advanced Materials shows on its market-data page a PE of about 98.7x and PB of about 6.9x.

[Inference] This shows a very simple fact: even compared with peer new-materials stocks that are not cheap to begin with, Bowei's valuation is clearly more expensive. Calculated independently from the 165.8 yuan/share you gave and 2025 net profit, net assets, revenue, and EBITDA, Bowei's static PE is about 198x, PB about 25x, P/S about 38x, and EV/EBITDA about 129x; and since 2025 free cash flow was negative, P/FCF has in the conventional sense lost its reference value.

[Opinion] Relative valuation gives you no protection; it only reminds you that the market has already pulled forward many years of the best case.

Method 3: Asset or liquidation value

[Fact] Restated 2025 net assets attributable to shareholders were 1.715 billion yuan, or about 6.56 yuan of net assets per share; total assets were 2.265 billion yuan, or about 8.66 yuan of total assets per share. The company has a high proportion of fixed assets, with heavy investment in construction in progress and specialized equipment.

[Inference] For this kind of specialized-equipment, process-driven materials company, the "liquidation value" of book assets usually does not exceed book net assets by much, because many machines and production lines have limited secondhand resale value; that is, the floor support from an asset-based approach is not strong. On an asset basis alone, the price you pay today is almost entirely buying "future growth expectations," not "protection from existing assets."

Combining the three methods, my conclusion is: Ideal buy-price range: 7-12 yuan/share; Acceptable long-term-holding price range: 12-25 yuan/share; Clearly overvalued price range: above 50 yuan/share.

Here I deliberately set the ceiling wider than the neutral DCF value to leave room for new-business delivery and sentiment premium; but even so, 165.8 yuan still falls in the extremely overvalued zone.

On margin of safety, there is only one most-fragile assumption: the new growth the market expects must materialize into cash flow very fast, very smoothly, and at high quality. If any two of three things happen, growth below expectations, margin pullback, or valuation-multiple contraction, this investment can easily produce a permanent loss of capital. Yes, this is the classic case of: a good company at a bad price.

Risks, Comparisons, and Investment Checklist

First, the most important counterargument, namely "why this investment might be wrong." The strongest bull case would roughly be: Bowei is not priced on its 219-million-yuan 2025 profit, but on the large-platform value of years of MLCC small-particle nickel-powder upgrades, photovoltaic copper-for-silver substitution, copper-based materials, and other new applications. The company has both a technical moat and ongoing expansion, and is preparing an H-share listing, suggesting it is on the eve of a leap from a "niche materials company" to a "platform new-materials company." Its Q1 2026 revenue grew 64.02% year-on-year and net profit attributable to shareholders grew 49.64% year-on-year, which seems to validate this too.

I admit this bull case is not entirely without merit. The problem is: value investing asks "even if this only delivers seventy percent, is today's price still worthwhile"; whereas Bowei's price today looks more like "you must assume it delivers almost in full, and delivers fast." That is not a margin of safety, but a high-odds bet placed on the unfavorable side.

The permanent-loss-of-capital risks that truly belong on the checklist fall, in my view, into seven main categories:

Compared with other opportunities, my answer is also clear. Against Yuean New Materials, the peer that looks more like a true comparable, Bowei does have more vertical MLCC nickel-powder characteristics, but its valuation is significantly more expensive; against a broad index, Bowei's current earnings yield is extremely low, meaning that what you get by buying today is not current cash return but a very-long-dated pull-forward of growth; against risk-free yields or high-grade bonds, Bowei offers no "visible right now" return protection. The only way it can win is if high growth and high cash conversion both hold over the next few years at the same time. For a value investor, that is not solid enough.

If I could only hold 5 assets, I would not put it in the portfolio. Not because the company is bad, but because the price is bad. In true long-term investing, the worst sin is not short-term volatility but buying, at an extremely high price, a company that has not yet proven it can steadily spew free cash flow.

Finally, the checklist:

What fact would make me admit today's "Avoid" verdict is wrong? Only three: First, the company truly builds out its new businesses over the next two to three years, with Owner Earnings rising steadily above 400-500 million yuan; Second, the returns on newly commissioned projects are high enough, with ROIC steadily rising above 15%-20%; Third, operating cash flow stays well above 70%-80% of net profit for several consecutive reporting periods, proving growth no longer heavily consumes cash. Until these things actually happen, I will not change the conclusion just because the stock is strong.

Final Investment Conclusion

[Final Rating] Avoid

[One-Sentence Investment Thesis] Bowei New Materials is a high-end metal powder company with real technical barriers, but buying at today's price of about 165.8 yuan means paying almost entirely for long-dated optimistic expectations rather than for already-proven free cash flow.

[Core Bull Reasons]

• The company has real technical accumulation in high-end electronic metal powders, holds 181 valid patents, and led the "Capacitor Electrode Nickel Powder" industry standard.

• Profit recovered clearly in 2025, and Q1 2026 revenue and profit continued their high growth.

• Nickel-based, copper-based, and alloy powders, along with photovoltaic silver reduction/substitution, provide the company with new growth space.

• The balance sheet is not yet fragile, the net-debt burden is manageable, and near-term survival risk is low.

[Core Bear Reasons]

• The current valuation is extremely expensive, with static PE around 198x and PB around 25x, far above its current profit- and cash-flow-bearing capacity.

• Free cash flow and Owner Earnings are unstable, 2025 FCF was negative, and Q1 2026 operating cash flow again saw a large outflow.

• Earnings are sensitive to the cycle, customer mix, and working capital, and the company posted a loss in 2023.

• Governance and disclosure quality have flaws, with regulatory cautions and a warning letter received over the past three years.

• Capital allocation is not pure enough, with a 2025 related-party investment of limited relevance to the core business, and future H-share preparation carrying a dilution expectation.

[Key Assumptions] For this investment to work, all of the following must hold at once: the company's new businesses keep ramping in 2026-2028; returns on new capacity are well above the cost of capital; operating cash flow improves markedly; and the valuation premium can be genuinely absorbed by future cash flow rather than sustained only by sentiment.

[Fair Buy Price] 7-12 yuan/share. The basis: requiring at least a 30% margin of safety, my neutral and conservative intrinsic-value ranges are roughly 10-18 yuan and 4-7 yuan, and taking the conservative bound downward better fits value-investing discipline. On a looser basis, 12-25 yuan/share can serve as a long-term-holding watch range; above 50 yuan is already clearly overvalued.

[Target Holding Period] If one must invest in this name, it should be assessed over an industry-delivery horizon of 3-5 years or more, not 3 months. Given the horizon you provided, I would not advise treating it as a "value-investing buy."

[Expected Annualized Return] The following is a rough scenario estimate for "buying at the current price and the valuation reverting to my estimated value ranges over the next 5 years": Conservative scenario: about -45% to -50%/year. Neutral scenario: about -35% to -40%/year. Optimistic scenario: about -15% to -25%/year. These returns are negative not because the business is sure to deteriorate, but because the price you pay today is already far above the intrinsic value I can accept.

[Maximum Loss Risk] If the company fails to deliver high profit growth over the next two to three years, and the market compresses the valuation from 170-200x PE to the 40-60x range more common for growth-materials stocks, the stock could see a long-term drawdown of 70%-80% or more. If it reverts to the extreme of asset and ordinary-manufacturing pricing, the loss could run deeper.

[Tracking Metrics] Focus on these 8 metrics:

• The ratio of operating cash flow to net profit attributable to shareholders.

• Whether free cash flow stays positive on a sustained basis.

• Whether the growth rates of accounts receivable, prepayments, and inventory keep outpacing revenue.

• Changes in revenue, gross margin, and volume for nickel-based and copper-based products.

• Whether the export share and export gross margin can be maintained.

• The commissioning progress and ramp-to-full returns of new expansion projects.

• Related-party investments, H-share listing progress, and potential dilution.

• Whether regulatory or disclosure problems recur.

[Triggers for Reassessment]

• Operating cash flow markedly weaker than profit for two or more consecutive reporting periods.

• Receivables and prepayments continuing to balloon quickly.

• Adverse changes in major-customer orders or customer concentration.

• New businesses like copper-for-silver and photovoltaics failing to qualify as expected.

• H-share financing materially diluting existing shareholders' interests.

• Recurrence of regulatory penalties, major corrections, or governance problems.

• ROIC failing to improve after new projects come online, instead dragging on cash flow.

[Final Recommendation] From the standpoint of "acquiring a whole business for the long term," Bowei New Materials is not a company you cannot research, but a company not worth buying at this price. It has technical content and growth options, but its current valuation has written too much of the future into today's price. What you really need to wait for is not the next story, but a lower price, more cash-flow validation, and higher governance credibility.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.